Aurobindo Pharma Ltd

(AUROPHARMA)

Aurobindo Pharma Acquires GLS Stake Amid FDA News - 18 Sep, 2024

Aurobindo Pharma announced its acquisition of the remaining 49% stake in GLS Pharma for Rs 22.5 crore. However, shares fell 1% following the USFDA's issuance of an Establishment Inspection Report for its injectable facility in Andhra Pradesh.

LIC Reduces Stake in Aurobindo Pharma Significantly - 14 Sep, 2024

LIC has decreased its stake in Aurobindo Pharma from 5.01% to 2.265%, selling over 1.61 crore shares. Aurobindo's shares rose slightly by 0.47% following the announcement.

Aurobindo Pharma's Subsidiary Receives FDA Approval - 12 Sep, 2024

Aurobindo Pharma's subsidiary, Eugia Steriles, received FDA approval for its injectable facility and the Lidocaine Hydrochloride Injection, marking a significant milestone.

Aurobindo Pharma Subsidiary Gains USFDA Approval - 11 Sep, 2024

Aurobindo Pharma's step-down subsidiary, Eugia Steriles, received USFDA approval for Lidocaine Hydrochloride injection. The approval follows a successful inspection of their new injectable facility in Andhra Pradesh.

Aurobindo Pharma Donates for Flood Relief Efforts - 07 Sep, 2024

Aurobindo Pharma Ltd, through its philanthropic arm, has donated Rs 10 crore to support flood relief operations in Telangana and Andhra Pradesh, contributing Rs 5 crore each to both states' relief funds.

Aurobindo Pharma Begins Production of Key Antibiotic Ingredient - 06 Sep, 2024

Aurobindo Pharma has received clearance to commence production of KSM penicillin G, a crucial component in manufacturing various common antibiotics.

Aurobindo Pharma Expands Biologics and Specialty Operations - 03 Sep, 2024

Aurobindo Pharma plans to invest Rs 1,000 crore in a biologics plant with a capacity of 30 million vials. The company aims to enhance its specialty business and biosimilar development while expanding operations in emerging markets. Recent acquisitions and investments in manufacturing facilities underscore its growth strategy.

Aurobindo Pharma Reports Strong Q1 Growth - 02 Sep, 2024

Aurobindo Pharma focuses on biosimilars and R&D, reporting a 61% net profit increase in Q1 FY25. The company plans significant investments in capacity expansion and biologics manufacturing.

Aurobindo Pharma Continues Upward Trend - 28 Aug, 2024

Aurobindo Pharma Ltd is experiencing its fifth consecutive session of gains, trading at Rs 1566.95, up 0.97% on the day. The stock has surged 89.06% over the past year, outperforming both the NIFTY and Nifty Pharma indices. The stock volume today is lower than the monthly average, with a PE ratio of 47.56 based on TTM earnings.

Aurobindo Pharma Issues Recall for Pain-Relief Medication - 27 Aug, 2024

Aurobindo Pharma USA Inc is recalling 240 bottles of Healthy Living Acetaminophen, Aspirin, and caffeine tablets due to missing labels, as reported by the US FDA. This Class 1 recall indicates potential serious health risks associated with the product.

Aurobindo Faces Recall and FDA Warning Issues - 26 Aug, 2024

Aurobindo Pharma's subsidiary Eugia received a warning letter from the USFDA for manufacturing violations. Additionally, Aurobindo Pharma USA recalled 240 bottles of medication due to missing labels.

USFDA Issues Warning to Aurobindo Pharma Subsidiary - 25 Aug, 2024

Eugia Pharma, a subsidiary of Aurobindo Pharma, received a warning letter from the USFDA for significant manufacturing lapses and data integrity issues at its Hyderabad plant. The FDA may withhold approval of new applications until compliance is confirmed.

USFDA Issues Warning to Aurobindo Pharma Subsidiary - 22 Aug, 2024

The USFDA flagged Aurobindo Pharma's subsidiary Eugia Pharma Specialities for data integrity issues at its Telangana facility, citing failures in testing and falsified records. This raises concerns about compliance and quality assurance.

USFDA Warning Letter Impacts Aurobindo Pharma - 21 Aug, 2024

Aurobindo Pharma's Eugia Unit-3 received a USFDA warning letter citing significant data integrity issues. The facility contributes 30% of total revenue, and remediation may take over 18 months. Shares fell 2.48% to ₹1,499.85.

Aurobindo Pharma's China Plant Production Timeline - 20 Aug, 2024

Aurobindo Pharma's China facility is set to begin small-scale production in Q3 FY25, with full-scale output expected in FY26. The company is also progressing on its Pen-G plant in Andhra Pradesh, aiming for significant production ramp-up from October 2024.